BIOMAT Database Logo BIOMAT Database Logo

[The effect of anti-arrhythmia agents on ventricular arrhythmias arising as a consequence of disorders in the myocardial blood supply]. 1990

E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin

The protective and therapeutic effects of some antiarrhythmic drugs of classes I-IV were studied in the experiments on 103 cats and 75 dogs. The antiarrhythmic drugs of classes 1a (N-propylaimaline bromide, aimaline, ethacizine), 1b (trimecaine) and IV (finoptine) were shown to prevent with various effectiveness the occurrence of early occlusion and reperfusion ventricular arrhythmias. The antiarrhythmic drugs of classes II (anapriline) and III (cordaron) proved to be ineffective in these cases. Ventricular arrhythmia in dogs occurring at the late stage of experimental infarction is reliably relieved in all cases with the antiarrhythmic drugs of class 1a, in most cases--those of classes 1b and III. The antiarrhythmic drugs of classes II and III are ineffective on this model. The experimental results analysed with regard to modern concepts of the genesis of modelled arrhythmias may be used as the experimental basis for a rational choice of antiarrhythmic drugs.

UI MeSH Term Description Entries
D008297 Male Males
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D015428 Myocardial Reperfusion Injury Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm. Reperfusion Injury, Myocardial,Injury, Myocardial Reperfusion,Myocardial Ischemic Reperfusion Injury,Injuries, Myocardial Reperfusion,Myocardial Reperfusion Injuries,Reperfusion Injuries, Myocardial

Related Publications

E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Anti-arrhythmia agents in ventricular arrhythmias].
April 1989, Nederlands tijdschrift voor geneeskunde,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
January 1996, Zeitschrift fur Kardiologie,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Drug information: agents for the treatment of arrhythmias. Therapeutic main group: anti-arrhythmia agents. 16. (3). Anti-arrhythmia agents with action on ventricular arrhythmias].
January 1981, Sygeplejersken,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Pyromecaine--a new anti-arrhythmia preparation improving myocardial blood supply].
April 1985, Kardiologiia,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Arrhythmias caused by anti-arrhythmia agents].
June 1992, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Anti-arrhythmia agents in the therapy of ventricular arrhythmias in the post-CAST era].
September 1994, Schweizerische medizinische Wochenschrift,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Effect of nonsteroidal anti-inflammatory agents on the myocardial blood supply and oxygen regimen].
January 1985, Farmakologiia i toksikologiia,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
Anti-arrhythmic effects of amiodarone and desethylamiodarone on malignant ventricular arrhythmias arising as a consequence of ischaemia and reperfusion in the anaesthetised rat.
April 1989, Cardiovascular research,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
A new anti-arrhythmia agent (Ro 2-5803): its effect on ventricular arrhythmias.
June 1961, Journal of the American Geriatrics Society,
E I Gendenshteĭn, and Ia V Kostin, and N N Markelova, and V P Balashov, and V E Oleĭnikov, and A V Perevarin
[Therapy of arrhythmias. New anti-arrhythmia agents].
January 1981, Verhandlungen der Deutschen Gesellschaft fur Herz- und Kreislaufforschung,
Copied contents to your clipboard!